News

As lipid management in the United States under goes transition in response to new guideline recommendations and expanding lipid-lowering therapy options, the Duke Clinical Research Institute (DCRI) announced a new study to better understand contemporary lipid management as well as the beliefs and attitudes of patient and providers regarding cholesterol, cardiovascular risk assessment, and options for lipid treatments.

While sales of Gilead Science’s popular hepatitis C drug, Harvoni, had been performing well for several months, the trend has reversed of late. Hepatitis C drug Sovaldi, also from Gilead, has also hit some bumps in the road – in both the U.S. and China.

Antibiotic resistance is a growing problem, both in the United States and across the world. The main driving factors behind antibiotic resistance are the overuse and misuse of antibiotics, according to the Centers for Disease Control and Prevention.

Rep. Steve Stivers (R-Ohio) and Rep. Peter Welch (D-Vt.) have re-introduced the Fair Access for Safe and Timely (FAST) Generics Act to what they say will increase consumer access to generic drugs, boost market competition and ultimately save consumers money.

More adults than children in the United States now take medication for attention deficit hyperactivity disorder (ADHD), according to new data.

Global prescription drug sales should reach nearly $1 trillion by 2020, thanks in part to FDA approvals of breakthrough drugs for cancer, hepatitis C and other diseases, a new report finds.

Infants and children who are given prescription acid-reducing medications face a substantially higher risk of developing Clostridium difficile infection, according to a study published recently in the online edition of Clinical Infectious Diseases.

Drug shortages are significant public health threats. They can delay, or even deny, critical care for patients. Here are the four drugs in shortage that are among the most problematic.